Thermo Fisher Scientific Inc. announced that its Olink® Explore Platform has been selected by the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest human proteomics study of its kind. This landmark project aims to analyze more than 5,400 proteins from 600,000 samples, driving the discovery of new protein biomarkers.
The unprecedented scale of this project underscores the potential of Thermo Fisher’s next-generation proteomics solution to deepen understanding of disease and advance life sciences research. The Olink Explore Platform, acquired by Thermo Fisher in July 2024, is designed for deep analysis of thousands of proteins in the human body, enabling researchers to study their role in various diseases.
The UKB-PPP is scheduled to begin in Q1 2025, with proteomic data becoming available to UK Biobank-approved researchers in staggered releases starting in 2026, and the full dataset in 2027. This collaboration validates the strategic importance of the Olink acquisition and positions Thermo Fisher at the forefront of precision medicine and biomarker discovery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.